89 related articles for article (PubMed ID: 16492207)
1. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study.
Shimizu H; Oh-I S; Tsuchiya T; Ohtani KI; Okada S; Mori M
Diabet Med; 2006 Mar; 23(3):253-7. PubMed ID: 16492207
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
Aso Y; Yamamoto R; Suetsugu M; Matsumoto S; Wakabayashi S; Matsutomo R; Takebayashi K; Inukai T
Diabet Med; 2007 Sep; 24(9):962-8. PubMed ID: 17509067
[TBL] [Abstract][Full Text] [Related]
3. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
4. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
[TBL] [Abstract][Full Text] [Related]
8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
10. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
Oz O; Tuncel E; Eryilmaz S; Fazlioglu M; Gul CB; Ersoy C; Ocak N; Dirican M; Cangur S; Baran I; Imamoglu S
Endocrine; 2008 Feb; 33(1):101-5. PubMed ID: 18392690
[TBL] [Abstract][Full Text] [Related]
11. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Fujitaka K; Otani H; Jo F; Jo H; Nomura E; Iwasaki M; Nishikawa M; Iwasaka T
Endocr J; 2011; 58(6):425-32. PubMed ID: 21498915
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
13. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients.
Breslavsky A; Frand J; Matas Z; Boaz M; Barnea Z; Shargorodsky M
Clin Nutr; 2013 Dec; 32(6):970-5. PubMed ID: 23561637
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
Martens FM; Rabelink TJ; op 't Roodt J; de Koning EJ; Visseren FL
Eur Heart J; 2006 Jul; 27(13):1605-9. PubMed ID: 16762982
[TBL] [Abstract][Full Text] [Related]
15. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.
Gutierrez AD; Sathyanarayana P; Konduru S; Ye Y; Birnbaum Y; Bajaj M
Atherosclerosis; 2012 Jul; 223(1):204-8. PubMed ID: 22687642
[TBL] [Abstract][Full Text] [Related]
16. Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients.
Adachi T; Inoue M; Hara H; Maehata E; Suzuki S
J Endocrinol; 2004 Jun; 181(3):413-7. PubMed ID: 15171689
[TBL] [Abstract][Full Text] [Related]
17. Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: desirable side-effects of antidiabetic drugs.
Ghadge AA; Harke SM; Khadke SP; Diwan AG; Pankaj M; Kulkarni OP; Ranjekar PK; Kuvalekar AA
Diabetes Metab Syndr; 2014; 8(4):230-2. PubMed ID: 25450822
[TBL] [Abstract][Full Text] [Related]
18. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.
Kusunoki M; Tsutsumi K; Sato D; Nakamura A; Habu S; Mori Y; Morishita M; Yonemoto T; Miyata T; Nakaya Y; Nakamura T
Eur J Pharmacol; 2011 Oct; 668(3):486-91. PubMed ID: 21835171
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.
Iwase M; Asano T; Sasaki N; Yoshizumi H; Hiramatsu S; Sakai Y; Ogo A; Iida M
J Clin Pharm Ther; 2010 Aug; 35(4):401-8. PubMed ID: 20831543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
